| References: |
BD 1047 dihydrobromide is a selective antagonist of σ receptors. BD 1047 is demonstrated to attenuate the dystonia produced by the high affinity σ receptor ligands di-o-tolylguanidine and Haloperidol. BD 1047 is described to have similar activity at the σ-1 receptor to BD 1063 (sc-203838) and to show higher affinity at σ-2 than BD 1063. BD 1047 is demonstrated to antagonize the effects of Trazodone on neurotransmitter release. For the detailed information of BD1047.2HBr, the solubility of BD1047.2HBr in water, the solubility of BD1047.2HBr in DMSO, the solubility of BD1047.2HBr in PBS buffer, the animal experiment (test) of BD1047.2HBr, the cell expriment (test) of BD1047.2HBr, the in vivo, in vitro and clinical trial test of BD1047.2HBr, the EC50, IC50,and affinity,of BD1047.2HBr, For the detailed information of BD1047.2HBr, the solubility of BD1047.2HBr in water, the solubility of BD1047.2HBr in DMSO, the solubility of BD1047.2HBr in PBS buffer, the animal experiment (test) of BD1047.2HBr, the cell expriment (test) of BD1047.2HBr, the in vivo, in vitro and clinical trial test of BD1047.2HBr, the EC50, IC50,and affinity,of BD1047.2HBr, Please contact DC Chemicals. |
